Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 6/20 | 0.68 |
| ▸ | CNR1 | P21554 | 5/20 | 0.68 |
| ▸ | CNR2 | P34972 | 2/20 | 0.64 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.59 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.59 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5062778 | 0.86 | CNR1 (0.63) | TP53CNR1CNR2NPSR1PLA2G1B | |
| SCHEMBL5062794 | 0.85 | CNR1 (0.61) | TP53CNR1CNR2NPSR1PLA2G1B | |
| SCHEMBL5062757 | 0.85 | CNR1 (0.70) | TP53CNR1CNR2PLA2G1BMAPT | |
| SCHEMBL5064783 | 0.84 | CNR1 (0.64) | TP53CNR1CNR2NPSR1PLA2G1B | |
| SCHEMBL14043568 | 0.83 | CNR1 (0.68) | TP53CNR1NPSR1MAPTSMN1; SMN2 | |
| SCHEMBL5062722 | 0.83 | TP53 (0.67) | TP53CNR1NPSR1PLA2G1BMAPT | |
| SCHEMBL5062884 | 0.83 | CNR1 (0.62) | TP53CNR1CNR2MAPTSMN1; SMN2 | |
| SCHEMBL14542214 | 0.82 | CNR1 (0.75) | TP53CNR1MAPTSMN1; SMN2LMNA | |
| SCHEMBL5062827 | 0.82 | CNR1 (0.66) | TP53CNR1CNR2PLA2G1BMAPT | |
| SCHEMBL5064603 | 0.82 | CNR1 (0.66) | TP53CNR1CNR2MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040033253-A1 | Acyl opioid antagonists | PURDUE PHARMA L.P. | 2004-02-19 | — | — | US | claimed |
| WO-2009075691-A1 | CB-1 MODULATING COMPOUNDS AND THEIR USE | ACADIA PHARMACEUTICALS INC. (US) | 2009-06-18 | — | — | WO | disclosed |
| WO-2008118141-A2 | USE OF CANNABINOID MODULATING COMPOUNDS IN COMBINATION WITH OTHER THERAPEUTIC COMPOUNDS FOR ADJUNCTIVE THERAPY | ACADIA PHARMACEUTICALS INC. (US) | 2008-10-02 | — | — | WO | disclosed |
| EP-1476141-B1 | TAMPER-RESISTANT TRANSDERMAL OPIOID DELIVERY DEVICES | EURO CELTIQUE SA (LU) | 2008-04-23 | — | — | EP | disclosed |
| US-20080090805-A1 | CB-1 MODULATING COMPOUNDS AND THEIR USE | ACADIA PHARMACEUTICALS INC. (US) | 2008-04-17 | — | — | US | disclosed |
| US-20080090805-A1 | CB-1 MODULATING COMPOUNDS AND THEIR USE | ACADIA PHARMACEUTICALS INC. (US) | 2008-04-17 | — | — | US | disclosed |
| US-20080090805-A1 | CB-1 MODULATING COMPOUNDS AND THEIR USE | ACADIA PHARMACEUTICALS INC. (US) | 2008-04-17 | — | — | US | disclosed |
| US-20070106074-A1 | Iron catalyzed cross-coupling reactions of imidoyl derivatives | ACADIA PHARMACEUTICALS | 2007-05-10 | — | — | US | disclosed |
| US-20070105819-A1 | CB-1 modulating compounds and their use | ACADIA PHARMACEUTICALS, INC. | 2007-05-10 | — | — | US | disclosed |
| US-20070105819-A1 | CB-1 modulating compounds and their use | ACADIA PHARMACEUTICALS, INC. | 2007-05-10 | — | — | US | disclosed |
| US-20070105819-A1 | CB-1 modulating compounds and their use | ACADIA PHARMACEUTICALS, INC. | 2007-05-10 | — | — | US | disclosed |
| WO-2007047737-A1 | CB-1 MODULATING COMPOUNDS AND THEIR USE | ACADIA PHARMACEUTICALS INC. (US) | 2007-04-26 | — | — | WO | disclosed |
| US-20040033253-A1 | Acyl opioid antagonists | PURDUE PHARMA L.P. | 2004-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070106074-A1 | Iron catalyzed cross-coupling reactions of imidoyl derivatives | SDHB, TFRC, SLC40A1 | TP53 4530/4885CNR1 4354/4885CNR2 4267/4885 |
| US-20070105819-A1 | CB-1 modulating compounds and their use | CNR1, CNR2, FAAH | TP53 4870/4885CNR1 1/4885CNR2 2/4885 |
| US-20040033253-A1 | Acyl opioid antagonists | OPRL1, OGFR, OPRK1 | TP53 4877/4885CNR1 128/4885CNR2 92/4885 |
| US-20080090805-A1 | CB-1 MODULATING COMPOUNDS AND THEIR USE | CNR1, CNR2, FAAH | TP53 4870/4885CNR1 1/4885CNR2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.